Bifogade filer
Kurs
-0,76%
Likviditet
3,00 MSEK
Kalender
Tid* | ||
2026-02-19 | 08:00 | Bokslutskommuniké 2025 |
2025-10-23 | 08:00 | Kvartalsrapport 2025-Q3 |
2025-07-17 | 08:00 | Kvartalsrapport 2025-Q2 |
2025-05-06 | - | Årsstämma |
2025-04-16 | 08:00 | Kvartalsrapport 2025-Q1 |
2025-02-20 | 08:00 | Bokslutskommuniké 2024 |
2024-10-24 | - | Kvartalsrapport 2024-Q3 |
2024-08-29 | - | Extra Bolagsstämma 2024 |
2024-07-18 | - | Kvartalsrapport 2024-Q2 |
2024-05-06 | - | X-dag ordinarie utdelning ADDV A 0.00 SEK |
2024-05-06 | - | X-dag ordinarie utdelning ADDV B 0.00 SEK |
2024-05-03 | - | Årsstämma |
2024-04-18 | - | Kvartalsrapport 2024-Q1 |
2024-02-22 | - | Bokslutskommuniké 2023 |
2023-10-26 | - | Kvartalsrapport 2023-Q3 |
2023-07-20 | - | Kvartalsrapport 2023-Q2 |
2023-05-08 | - | X-dag ordinarie utdelning ADDV A 0.00 SEK |
2023-05-08 | - | X-dag ordinarie utdelning ADDV B 0.00 SEK |
2023-05-05 | - | Årsstämma |
2023-04-20 | - | Kvartalsrapport 2023-Q1 |
2023-02-23 | - | Bokslutskommuniké 2022 |
2022-10-27 | - | Kvartalsrapport 2022-Q3 |
2022-07-22 | - | Kvartalsrapport 2022-Q2 |
2022-05-09 | - | X-dag ordinarie utdelning ADDV B 0.00 SEK |
2022-05-09 | - | X-dag ordinarie utdelning ADDV A 0.00 SEK |
2022-05-06 | - | Årsstämma |
2022-04-22 | - | Kvartalsrapport 2022-Q1 |
2022-02-24 | - | Bokslutskommuniké 2021 |
2021-10-27 | - | Kvartalsrapport 2021-Q3 |
2021-07-23 | - | Kvartalsrapport 2021-Q2 |
2021-04-26 | - | X-dag ordinarie utdelning ADDV B 0.02 SEK |
2021-04-26 | - | X-dag ordinarie utdelning ADDV A 0.02 SEK |
2021-04-23 | - | Kvartalsrapport 2021-Q1 |
2021-04-23 | - | Årsstämma |
2021-02-25 | - | Bokslutskommuniké 2020 |
2020-10-23 | - | Kvartalsrapport 2020-Q3 |
2020-07-24 | - | Kvartalsrapport 2020-Q2 |
2020-04-27 | - | X-dag ordinarie utdelning ADDV A 0.00 SEK |
2020-04-27 | - | X-dag ordinarie utdelning ADDV B 0.00 SEK |
2020-04-24 | - | Årsstämma |
2020-04-24 | - | Kvartalsrapport 2020-Q1 |
2020-02-20 | - | Bokslutskommuniké 2019 |
2019-10-22 | - | Kvartalsrapport 2019-Q3 |
2019-07-23 | - | Kvartalsrapport 2019-Q2 |
2019-04-26 | - | X-dag ordinarie utdelning ADDV B 0.00 SEK |
2019-04-26 | - | X-dag ordinarie utdelning ADDV A 0.00 SEK |
2019-04-25 | - | Årsstämma |
2019-04-25 | - | Kvartalsrapport 2019-Q1 |
2019-03-12 | - | Extra Bolagsstämma 2019 |
2019-02-21 | - | Bokslutskommuniké 2018 |
2018-10-25 | - | Kvartalsrapport 2018-Q3 |
2018-07-26 | - | Kvartalsrapport 2018-Q2 |
2018-05-04 | - | Kvartalsrapport 2018-Q1 |
2018-04-27 | - | X-dag ordinarie utdelning ADDV B 0.00 SEK |
2018-04-27 | - | X-dag ordinarie utdelning ADDV A 0.00 SEK |
2018-04-26 | - | Årsstämma |
2018-02-16 | - | Bokslutskommuniké 2017 |
2017-10-31 | - | Kvartalsrapport 2017-Q3 |
2017-07-26 | - | Kvartalsrapport 2017-Q2 |
2017-05-11 | - | Kvartalsrapport 2017-Q1 |
2017-04-28 | - | X-dag ordinarie utdelning ADDV B 0.00 SEK |
2017-04-28 | - | X-dag ordinarie utdelning ADDV A 0.00 SEK |
2017-04-27 | - | Årsstämma |
2017-02-23 | - | Bokslutskommuniké 2016 |
2016-11-14 | - | Kvartalsrapport 2016-Q3 |
2016-08-18 | - | Kvartalsrapport 2016-Q2 |
2016-05-23 | - | Kvartalsrapport 2016-Q1 |
2016-04-27 | - | X-dag ordinarie utdelning ADDV B 0.00 SEK |
2016-04-27 | - | X-dag ordinarie utdelning ADDV A 0.00 SEK |
2016-04-26 | - | Årsstämma |
2016-02-22 | - | Bokslutskommuniké 2015 |
2015-11-10 | - | Kvartalsrapport 2015-Q3 |
2015-08-17 | - | Kvartalsrapport 2015-Q2 |
2015-05-22 | - | Kvartalsrapport 2015-Q1 |
2015-04-27 | - | X-dag ordinarie utdelning ADDV A 0.00 SEK |
2015-04-24 | - | Årsstämma |
2015-02-19 | - | Bokslutskommuniké 2014 |
2014-11-05 | - | Kvartalsrapport 2014-Q3 |
2014-08-15 | - | Kvartalsrapport 2014-Q2 |
2014-05-21 | - | Kvartalsrapport 2014-Q1 |
2014-04-10 | - | X-dag ordinarie utdelning ADDV A 0.00 SEK |
2014-04-09 | - | Årsstämma |
2014-02-20 | - | Bokslutskommuniké 2013 |
2013-11-05 | - | Kvartalsrapport 2013-Q3 |
2013-08-08 | - | Kvartalsrapport 2013-Q2 |
2013-05-20 | - | X-dag ordinarie utdelning ADDV A 0.00 SEK |
2013-05-17 | - | Årsstämma |
2013-05-14 | - | Kvartalsrapport 2013-Q1 |
2013-02-21 | - | Bokslutskommuniké 2012 |
2012-11-06 | - | Kvartalsrapport 2012-Q3 |
2012-08-09 | - | Kvartalsrapport 2012-Q2 |
2012-05-14 | - | Kvartalsrapport 2012-Q1 |
2012-04-02 | - | X-dag ordinarie utdelning ADDV A 0.00 SEK |
2012-03-30 | - | Årsstämma |
2012-02-23 | - | Bokslutskommuniké 2011 |
2011-11-04 | - | Kvartalsrapport 2011-Q3 |
2011-08-10 | - | Kvartalsrapport 2011-Q2 |
2011-05-05 | - | Kvartalsrapport 2011-Q1 |
2011-04-06 | - | X-dag ordinarie utdelning ADDV A 0.00 SEK |
2011-04-04 | - | Årsstämma |
2011-02-07 | - | Bokslutskommuniké 2010 |
2010-11-04 | - | Kvartalsrapport 2010-Q3 |
2010-08-12 | - | Kvartalsrapport 2010-Q2 |
2010-05-21 | - | X-dag ordinarie utdelning ADDV A 0.00 SEK |
2010-05-20 | - | Årsstämma |
2010-05-06 | - | Kvartalsrapport 2010-Q1 |
2009-09-25 | - | X-dag ordinarie utdelning ADDV A 0.00 SEK |
2009-09-24 | - | Årsstämma |
2009-09-17 | - | Kvartalsrapport 2009-Q1 |
Beskrivning
Land | Sverige |
---|---|
Lista | First North Stockholm |
Sektor | Hälsovård |
Industri | Medicinteknik |
To enhance focus and efficiency, ADDvise is restructuring its two existing business areas, Lab and Healthcare, into separate operational units, each led by a dedicated director. This new structure is designed to optimize the organization, establish a clearer strategic focus, and strengthen the foundation for both organic growth and acquisitions. Additionally, the structure facilitates valuable knowledge-sharing across the group.
The Healthcare business area manufactures and supplies a diverse range of advanced medical technology, high-quality consumables, and pharmaceuticals. By combining innovative, proprietary products with established brands essential equipment is offered to both private and public healthcare providers. Fredrik Mella will take on the role of Head of Healthcare.
The Lab business area delivers comprehensive solutions for modern research environments, including laboratory furniture, safety ventilation, climate and clean rooms, and laboratory equipment. The products support global research and development, with a focus on the pharmaceutical industry and life sciences. Johan Seltborg will take on the role of Head of Lab.
"With this restructuring, we are strengthening our decentralized business model, focusing on the individual company. By reducing costs and improving efficiency, we enhance our ability to achieve both organic growth and growth through acquisitions. I am confident that this change will bring greater clarity, long-term value, and strengthen our capacity to achieve our growth strategy," says Staffan Torstensson, CEO of ADDvise.
Following this restructuring, ADDvise's group executive team will include Staffan Torstensson as CEO, Fredrik Mella as Head of Healthcare, Johan Seltborg as Head of Lab, Johan Irwe as interim CFO, and Hanna Myhrman as General Counsel and Head of M&A. Through cost and efficiency measures, annual costs for central functions are expected to decrease by SEK 18 million.
For further information, please contact:
Staffan Torstensson, CEO
+4670 433 20 19
staffan.torstensson@addvisegroup.se
About ADDvise Group
ADDvise is an international life science group. Operating a decentralised ownership model, we develop and acquire high quality companies within the business areas Lab and Healthcare. The Group comprises more than 20 companies and generates annual revenues of close to SEK 2 billion. ADDvise is listed on Nasdaq First North Premier Growth Market. Mangold Fondkommission AB, +46 8 503 015 50, CA@mangold.se,is the company's Certified Adviser. More information is available atwww.addvisegroup.com. (http://www.addvisegroup.com/)